- The P-III OA study involves assessing of tanezumab (2.5mg/5mg, SC) vs PBO in 849 patients in the ratio (1:1:1) with moderate-to-severe OA pain of the knee or hip across EU and Japan for 24 wks.
- The study showed a meeting in all 1EPs improvement in pain, physical function with well-tolerated results and has shown the ratio of RPOA type 1 to RPOA type 2 (2:1)
- Tanezumab is a mAb inhibiting nerve growth factor (NGF) and has received FDA’s Fast Track designation for OA pain and CLBP. In 2013, Pfizer and Lilly globally collaborated to jointly develop and commercialize tanezumab
Click here to read full press release/ article | Ref: Business Wire | Image: Telegraph India